[Development of thalidomide analogs for the treatment of multiple myeloma (MM)].
After the introduction of thalidomide (Thal) in the treatment of MM in 90's, several thalidomide analogs have been developed. Among them, CC-5013 (lenalidomide: Lenal) is the most potent and promising novel oral agent. Compared with Thal, Lenal is 50 to 2,000 times more potent at stimulating T cell proliferation and 50 to 100 times more potent at augumenting several cytokines. A phase I trial established a maximal tolerated oral dose for Lenal of 25 mg daily. Phase II study showed significant anti-MM activity of Lenal with less or no reports of significant somnolence, constipation, or neuropathy as with Thal therapy. Based on these findings, several phase III studies are on going internationally.
Chou
Takaaki
T
Department of Internal Medicine, Niigata Cancer Center Hospital.
D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D016207:Cytokines / Q000378:metabolism; D015195:Drug Design; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000077269:Lenalidomide; D008213:Lymphocyte Activation / Q000187:drug effects; D009101:Multiple Myeloma / Q000188:drug therapy*; D013601:T-Lymphocytes / Q000276:immunology; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
D016207:Cytokines; D007155:Immunologic Factors; D013792:Thalidomide; D000077269:Lenalidomide